ClinicalTrials.gg
RecruitingNCT04654975METABRECUpdated Jul 3, 2024

Metachronic Brain Metastases After Esophagectomy for Esophageal Cancer (METABREC)

An observational study in Esophageal Neoplasms, Esophagectomy and Brain Metastases, sponsored by Universitaire Ziekenhuizen KU Leuven. Recruiting at 8 sites in 6 countries. Per ClinicalTrials.gov, last updated 2024-07-03.

Sponsored by Universitaire Ziekenhuizen KU Leuven · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 7 months ago, but the record still lists the study as recruiting.
  • Started Jun 2020; still recruiting 6 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
10,000
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 90 studies in Esophageal Neoplasms with a site in Netherlands — 30 open to participants now, 36 under way, 5 of them phase 3. Esophageal Neoplasms · Netherlands.

Planned enrollment
Largest of 25
10,000 · median 200
Started
2020
with 3 others
Observational
25 of 90
11 open now
Primary completion
2025-03
later than 4 of 35 live
Registered
58th of 90
by date

Among the 90 studies in Esophageal Neoplasms with a site in Netherlands, this one has the largest planned enrollment of the 25 observational ones that give a count, is one of 4 that started in 2020, is one of 25 observational ones, reaches primary completion later than 4 of the 35 other live ones, and was the 58th registered.

Esophageal Neoplasms

1,874 studies on the registry are indexed under Esophageal Neoplasms; 502 are open to participants now.

Browse Esophageal Neoplasms studies →

Open to participants now

30 of the 90 studies in Esophageal Neoplasms with a site in Netherlands are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 387 Esophageal Neoplasms studies recruiting now, 245 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies in Esophageal Neoplasms with a site in Netherlands, or all of them as a file.
02

Study summary

Esophagectomy is the cornerstone of the curative treatment of esophageal carcinoma. Despite this treatment, patients can suffer from locoregional or distant metastatic disease and only a very selected group of patients can be cured: mostly those with recurrence in one single organ.

Brain metastases are rare after esophagectomy for cancer, but they have a serious impact on survival. Agressive treatment is often moren difficult for brain metastases compared to other metastases and some risk factors have been identified earlier.

There is an impression that the incidence of brain metastases in esophageal cancer patients has increased since the introduction of neoadjuvant treatment schemes. However, this is not clear yet. A potential explanation could be that chemotherapy disturbs the blood-brain-barrier, hereby facilitating the migration of tumor cells to the brain.

The purpose of this study is to retrospectively analyze the incidence and potential risk factors of brain metastases in patients who underwent esophagectomy for esophageal cancer. Patients treated between 2000 and 2019 will be included and outcome parameters are Odds Ratio for brain metastases (comparison between primary surgery and neoadjuvant treatment followed by surgery), time to recurrence and risk factors, number and characteristics of the brain metastases.

03

Conditions studied

  • Esophageal Neoplasms
  • Esophagectomy
  • Brain Metastases
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients receiving surgical treatment for esophageal cancer between 1 januari 2000 and 31 december 2019

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients receiving surgical treatment for esophageal cancer between 1 januari 2000 and 31 december 2019
  • All types of treatment followed by surgery, primary surgery or salvage surgery.
  • Adenocarcinoma or squamous cell carcinoma histology

Exclusion criteria

Exclusion Criteria:

  • other histology type than adenocarcinoma or squamous cell carcinoma
  • Hypopharyngeal carcinoma extending to the esophagus (requiring total laryngo-pharyngo-esophagectomy)
  • Early esophageal carcinoma (cT IS-1a N0 M0)
  • palliative esophagectomy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
10,000 participants (estimated)
Patient registry
No

Interventions

  • ProcedureEsophagectomy for esophageal cancer

    Surgical removal of (a part of) the esophagus and surgical reconstruction with another organ (mostly stomach, but may be colon or small bowel as well)

06

What researchers measure

Primary outcomes

  1. Odds ratio (OR) for brain metastasis

    Odds ratio (OR) for brain metastasis compared between primary surgery and neoadjuvant treatment plus surgery, OR for different neoadjuvant treatment regimes, corrected for gender and tumor factors (histology, stage, tumor differentiation,...) .

    Time frame: 1 January 2000 - 1 March 2020

Secondary outcomes

  1. Overall survival

    Overall survival after diagnosis of brain metastases stratified for treatment regimens applied.

    Time frame: 1 January 2000 - 1 March 2020

  2. Time to recurrence

    Time to recurrence, between incidence date of esophageal cancer and diagnosis of brainM+

    Time frame: 1 January 2000 - 1 March 2020

  3. Risk factors for single site brain metastasis

    such as different neoadjuvant treatment regimes, age, gender,and tumor factors (histology, stage, tumor differentiation,...)

    Time frame: 1 January 2000 - 1 March 2020

  4. Number of brain metastases

    Number of brain metastases

    Time frame: 1 January 2000 - 1 March 2020

  5. Characteristics of brain metastases

    solitary/multiple; location /side in the brain; treatment) and the effects on 'OS after recurrence' (e.g. is there a significant survival benefit in patients with brainM+ if they are treated with brain-surgery and/or stereotactic radiotherapy compared to non-treated BrainM+ or palliative treatments of brainM+

    Time frame: 1 January 2000 - 1 March 2020

07

Study locations

2 of 8 sites recruiting
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
    Not yet recruiting
    • Patricia Abraham · Contact
    • Wayne Hofstetter · Principal investigator
  • Universitair ziekenhuis Gent
    Gent, Belgium
    Not yet recruiting
    • Inge Vandenbroucke · Contact
    • Elke Van Daele · Principal investigator
  • Centre Hospitalier régional Universitaire de Lille
    Lille, France
    Not yet recruiting
    • Sébastien Degisors · Contact
    • Guillaume Piessen, PhD · Principal investigator
  • Saint James Hospital
    Dublin, Ireland
    Not yet recruiting
    • Noel E Donlon · Contact
    • John Reynolds · Principal investigator
  • Amsterdam UMC
    Amsterdam, Netherlands
    Recruiting
    • Daan Voeten · Contact
    • Mark Van Berge Henegouwen, PhD · Principal investigator
  • Zuyderland MC
    Heerlen, Netherlands
    Not yet recruiting
    • Julie Van Den Bosch, MD · Contact
    • Meindert Sosef, PhD · Principal investigator
  • Erasmus MC
    Rotterdam, Netherlands
    Not yet recruiting
    • x gao · Contact
    • Bas Wijnhoven, PhD · Principal investigator
  • Karolinska Institutet
    Stockholm, Sweden
    Recruiting
    • Biying Huang · Contact
    • Magnus Nilsson, PhD · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2020 (actual). Primary completion is estimated for Mar 2025, 57 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2020
First posted
Dec 4, 2020
StartActual
Jun 2, 2020
Primary completionEst.
Mar 31, 2025
CompletionEst.
Mar 31, 2025
Last update
Jul 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04654975
Responsible party
Sponsor
First posted
Dec 4, 2020
Start date
Jun 2, 2020
Primary completion
Mar 31, 2025 (estimated)
Completion
Mar 31, 2025 (estimated)
Last update
Jul 3, 2024

Study contacts

Lieven P Depypere, PhD
Contact
lieven.depypere@uzleuven.be
+32 16 346820
Johnny Moons, Msc
Contact
johnny.moons@uzleuven.be
+32 16 346820
Lieven P Depypere, PhD
principal investigator · UZ Leuven

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion